{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:39:09Z","timestamp":1767177549317,"version":"build-2238731810"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0141374","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T13:42:02Z","timestamp":1449841322000},"page":"e0141374","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Global Health Impact Index: Promoting Global Health"],"prefix":"10.1371","volume":"10","author":[{"given":"Nicole","family":"Hassoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"ref1","year":"2012"},{"key":"ref2","year":"2011"},{"key":"ref3","year":"2011"},{"key":"ref4"},{"key":"ref5","author":"A de Francisco","year":"2006"},{"key":"ref6","year":"2012"},{"key":"ref7","year":"2012"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.vaccine.2009.09.047","article-title":"Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles","volume":"28","author":"B Lee","year":"2010","journal-title":"Vaccine"},{"key":"ref9","article-title":"Results by cause both sexes all ages DALYs 2010","year":"2013"},{"issue":"Suppl 2","key":"ref10","doi-asserted-by":"crossref","first-page":"i58","DOI":"10.1136\/sextrans-2012-050689","article-title":"A new infectious disease model for estimating and projecting HIV\/AIDS epidemics","volume":"88","author":"L Bao","year":"2012","journal-title":"Sex Transm Infect"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2334-10-109","article-title":"Lives saved by global fund supported HIV\/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007","volume":"10","author":"R Komatsu","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"e0127818","DOI":"10.1371\/journal.pone.0127818","article-title":"Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries","volume":"10","author":"K Galactionova","year":"2015","journal-title":"PLoS One"},{"key":"ref13","first-page":"176","article-title":"Health inequalities and global justice","author":"N Hassoun","year":"2012"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thoraxjnl-2012-201663","article-title":"MDR, XDR, TDR tuberculosis: ominous progression","volume":"67","author":"ZT Udwadia","year":"2012","journal-title":"Thorax"},{"key":"ref15","year":"2009"},{"key":"ref16","year":"2011"},{"key":"ref17","year":"2013"},{"key":"ref18","year":"2013"},{"key":"ref19","year":"2008"},{"key":"ref20","year":"2008"},{"key":"ref21","year":"2011"},{"key":"ref22","year":"2013"},{"key":"ref23","year":"2010"},{"key":"ref24","year":"2010"},{"key":"ref25","year":"2011"},{"key":"ref26","year":"2011"},{"key":"ref27","year":"2010"},{"issue":"3","key":"ref28","first-page":"231","article-title":"Globalization, global justice and global health impact","volume":"28","author":"N Hassoun","year":"2014","journal-title":"Public Aff Q"},{"key":"ref29","unstructured":"United Nations Statistics Division. Children under 5 with fever being treated with anti-malarial drugs; 2006. Database: IndexMundi [internet]. Accessed: http:\/\/www.indexmundi.com\/vietnam\/malaria-treatment.html<\/ext-link>."},{"key":"ref30","year":"2011"},{"key":"ref31","year":"2010"},{"key":"ref32","year":"2012"},{"key":"ref33","year":"2010"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3201\/eid1303.061400","article-title":"Worldwide emergence of extensively drug-resistant tuberculosis","volume":"13","author":"S Shah","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"9428","key":"ref35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(04)16586-0","article-title":"Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial","volume":"364","author":"C Laurent","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QAI.0b013e3181a56e81","article-title":"The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals","volume":"51","author":"NT Annan","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"16","key":"ref37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/08892220260387922","article-title":"Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients","volume":"18","author":"A Kebba","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1310\/hct1304-228","article-title":"Efficacy of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-na\u00efve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK","volume":"13","author":"E DeJesus","year":"2012","journal-title":"HIV Clin Trials"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"JE Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"ES Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1086\/656363","article-title":"Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatmentnaive, HIV-infected subjects: week 48 data from the Altair study","volume":"51","author":"RL Puls","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref42","unstructured":"Miro JM, Manzardo C, Ferrer E, Crespo A, Lonca M, Podzamczer D, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients taking antiretroviral regimens based on efavirenz, lopinavir-ritonavir, and atazanavir-ritonavir: 48-week results of a randomized controlled trial (the Advanz-3 trial). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention [abstract MOPE165]. Rome, Italy: International AIDS Society; 2011. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25831464<\/ext-link>. Accessed 18 Sep 2015."},{"issue":"9787","key":"ref43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial","volume":"378","author":"JM Molina","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1545109709344352","article-title":"Tenofovir-emtricitabine efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients","volume":"8","author":"R Landman","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dkn471","article-title":"High rate of early virological failure with the once-daily tenofovir\/lamivudine\/nevirapine combination in naive HIV-1-infected patients","volume":"63","author":"D Rey","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial","volume":"16","author":"V Soriano","year":"2011","journal-title":"Antivir Ther"},{"issue":"16","key":"ref47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":"Antiretroviral therapies in women after single-dose nevirapine exposure","volume":"363","author":"S Lockman","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/aid.2011.0092","article-title":"Evaluation of the safety and effectiveness of nevirapine plus coformulated Tenofovir\/Emtricitabine as first-line therapy in routine clinical practice","volume":"28","author":"G Vallecillo","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jac\/dkp322","article-title":"Pharmacokinetics and 48 week efficacy of low-dose lopinavir\/ritonavir in HIV-infected children","volume":"64","author":"T Puthanakit","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"KY Smith","year":"2009","journal-title":"AIDS"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1542\/peds.2006-3078","article-title":"Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects","volume":"121","author":"X Saez-Llorens","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct0901-1","article-title":"Seven-year efficacy of a lopinavir\/ritonavir-based regimen in antiretroviral-na\u00efve HIV-1-infected patients","volume":"9","author":"RL Murphy","year":"2008","journal-title":"HIV Clin Trials"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.antiviral.2009.11.008","article-title":"Similar antiviral efficacy and tolerability between efavirenz and lopinavir\/ritonavir, administered with abacavir\/lamivudine (Kivexa), in antiretroviral-na\u00efve patients: a 48-week, multicentre, randomized study (Lake Study)","volume":"85","author":"P Echeverr\u00eda","year":"2010","journal-title":"Antiviral Res"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effect, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"FA Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"ref55","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/INF.0b013e31821752d6","article-title":"Lopinavir\/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine\/emtricitabine resistance at the time of virologic failure","volume":"30","author":"P Frange","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials","volume":"60","author":"CJ Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1742-1241.2011.02807.x","article-title":"A randomised comparison of safety and efficacy of nevirapine vs. atazanavir\/ritonavir combined with tenofovir\/emtricitabine in treatment-na\u00efve patients","volume":"65","author":"E Dejesus","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"9692","key":"ref58","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"key":"ref59","unstructured":"Campbell TB, Smeaton LN, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. Efficacy and safety of EFV with either co-formulated 3TC\/ZDV or FTC\/TDF for initial treatment of HIV-1-infected men and women in diverse multinational settings: ACTG PEARLS Study. 18th Conference on Retroviruses and Opportunistic Infections [abstract 149LB]. Boston, Massachusetts: Foundation for Retrovirology and Human Health; 2011. Available: http:\/\/journals.plos.org\/plosmedicine\/article?id=10.1371\/journal.pmed.1001290<\/ext-link>. Accessed 22 Oct 2015."},{"issue":"6","key":"ref60","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"C Cohen","year":"2011","journal-title":"AIDS"},{"issue":"7","key":"ref61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0b013e3283463c07","article-title":"Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection","volume":"25","author":"CL Gay","year":"2011","journal-title":"AIDS"},{"issue":"7","key":"ref62","first-page":"519","article-title":"Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report","volume":"44","author":"T Pensi","year":"2007","journal-title":"Indian Pediatr"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1471-2334-8-136","article-title":"Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with\/without prior co-administration of rifampicin: a 144-week prospective study","volume":"8","author":"W Manosuthi","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0b013e318263277e","article-title":"Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)","volume":"61","author":"E Gotuzzo","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"M Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3851\/IMP2443","article-title":"A randomized comparison of second-line lopinavir\/ritonavir monotherapy versus tenofovir\/lamivudine\/lopinavir\/ritonavir in patients failing NNRTI-regimens: the HIV STAR study","volume":"17","author":"T Bunupuradah","year":"2012","journal-title":"Antivir Ther"},{"issue":"5","key":"ref67","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1468-1293.2009.00786.x","article-title":"Nevirapine\/zidovudine\/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir\/zidovudine\/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts","volume":"11","author":"P Munderi","year":"2010","journal-title":"HIV Med"},{"issue":"2","key":"ref68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"JE Gallant","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudine\/lamivudine: 96-week results from the MERIT study","volume":"11","author":"J Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1471-8847.2011.00314.x","article-title":"Global health impact: A basis for labeling and licensing campaigns?","volume":"12","author":"N Hassoun","year":"2012","journal-title":"Dev World Bioeth"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1758-2652-13-35","article-title":"A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries","volume":"13","author":"B Waning","year":"2010","journal-title":"J Int AIDS Soc"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0148946","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0141374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T21:17:52Z","timestamp":1653772672000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0141374"}},"subtitle":[],"editor":[{"given":"Delmiro","family":"Fernandez-Reyes","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0141374","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]}}}